{"schema_version":"secwatch.filing_event.v1","accession":"0001082554-25-000036","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.745091+00:00","generated_at":"2026-05-17T01:34:25.028992+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"United Therapeutics reports record Q3 revenue $799.5M (+7% YoY); EPS $7.16 diluted, TETON-2 breakthrough","bullets":["Revenue $799.5M (+7% YoY); net income $338.7M (+10%); diluted EPS $7.16 vs $6.39.","Tyvaso DPI sales $336.2M (+22% YoY) driving total Tyvaso growth to $478M (+10%).","Orenitram $131.1M (+16%); Unituxin $47.9M (-22%) offset by price increases.","TETON-2 study in IPF shows breakthrough results; could significantly broaden therapeutic reach.","Entered $1B accelerated share repurchase in Aug 2025; received 2.6M shares in Q3 (combined $2B since Mar 2024)."],"urls":{"canonical":"https://secwatch.observer/filing/0001082554-25-000036","json":"https://secwatch.observer/filing/0001082554-25-000036.json","markdown":"https://secwatch.observer/filing/0001082554-25-000036.md","text":"https://secwatch.observer/filing/0001082554-25-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000108255425000036/0001082554-25-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000108255425000036/uthr-20251029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:34:25.028992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}